Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. The company is headquartered in Los Angeles, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-12.46M |
| Operating Margin | 0.00% |
| Return on Equity | -366.40% |
| Return on Assets | -13.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.56 |
| Price-to-Book | 0.48 |
| Price-to-Sales (TTM) | 70327.55 |
| EV/Revenue | 93386.37 |
| EV/EBITDA | -7.37 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $24.19M |
| Float | $14.71M |
| % Insiders | 38.17% |
| % Institutions | 4.60% |